Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)
Lung Cancer Update
00:00
Is There a Second-Line Therapy for BRAF V600E?
In terms of next gen targeted drugs, we've seen a lot come and go. I don't know if it would be anything different, but really we want more out of those spaces. You'll get a little bit older. Some of the population that grows back during chemo is resistant might retain sensitivity to targeted agents. So for BRAF V600E after Dabraffin of Tremendib, and I've had also similar patients where really get really a lot of mileage out of targeted therapy,. at progression, for me, it's chemo IO.
Transcript
Play full episode
